Charles L. Beach

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*

Valeria Santini, Pierre Fenaux, Ghulam J. Mufti et al. · European Journal Of Haematology · 2010 · 129 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C

Pierre Fenaux, Norbert Gattermann, John F. Seymour et al. · British Journal of Haematology · 2010 · 74 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

B. Douglas Smith, Charles L. Beach, Dalia Mahmoud et al. · Experimental Hematology and Oncology · 2014 · 33 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris

Udho Thadani, Stephen P. Glasser, Neville Bittar et al. · The American Journal of Cardiology · 1994 · 21 citations

Medicine, Pharmacology, Pharmacotherapy +10

A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment

Eric Laille, Sanjay Goel, Alain C. Mita et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2013 · 18 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17